<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176291</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13120236</org_study_id>
    <secondary_id>R34MH101371</secondary_id>
    <nct_id>NCT02176291</nct_id>
  </id_info>
  <brief_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</brief_title>
  <acronym>IRLGREY-B</acronym>
  <official_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan F. Karp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this project are to examine the feasibility, safety, tolerability and&#xD;
      clinical effect of low-dose buprenorphine as a novel treatment for late-life&#xD;
      treatment-resistant depression and to develop preliminary data about mechanism of action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to one half of older patients with major depression develop Late-Life Treatment Resistant&#xD;
      Depression (LL-TRD). Consequences of LL-TRD include suicide, worsened medical conditions,&#xD;
      increased caregiver burden, and higher all-cause mortality. The development and testing of&#xD;
      novel-mechanism pharmacotherapies is a public health priority embraced by National Institute&#xD;
      of Mental Health (NIMH). Among the neuropeptidergic transmitters, opioids are known to&#xD;
      modulate mood, and this system is often altered in patients with major depression. Targeting&#xD;
      the opiate system in LL-TRD may positively modulate a system in which there is age-associated&#xD;
      imbalance between circulating opiates and the density and binding affinity of mu and kappa&#xD;
      opiate receptors. Buprenorphine (BPN) is an antagonist at the kappa opiate receptor and a&#xD;
      partial agonist at the mu opiate receptor. Either, or both, of these pharmacodynamic actions&#xD;
      may underlie its putative antidepressant effects. Our research group has open pilot data from&#xD;
      15 older adults with prospectively demonstrated treatment resistance to venlafaxine who were&#xD;
      exposed to low-dose BPN, suggesting a clinically meaningful antidepressant effect. In&#xD;
      addition, since BPN: 1) is available in sublingual formulation and 2) has a favorable safety&#xD;
      and pharmacokinetic profile, it is an attractive candidate to re-purpose as a molecule for&#xD;
      LL-TRD. Thus, the overarching aims of this project are to examine the feasibility, safety,&#xD;
      tolerability and clinical effect of low-dose BPN as a novel treatment for LL-TRD and to&#xD;
      develop preliminary data about mechanism of action (MOA).&#xD;
&#xD;
      The overarching aims are to examine the feasibility, safety, and tolerability of&#xD;
      buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression&#xD;
      (LL-TRD). This also involves using translational tools of modern neurobiology (fMRI) to&#xD;
      rapidly obtain proof-of-concept support for further clinical development. Formal dosing&#xD;
      schedules in the use of buprenorphine have yet to be thoroughly established. This study hopes&#xD;
      to determine optimal dosing strategies to improve acceptability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Measure of depression severity, range of 0-60&#xD;
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.&#xD;
Greater mean change represents better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory--Anxiety Subscale (BSI)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.&#xD;
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>suboxone</other_name>
    <other_name>buprenex</other_name>
    <other_name>temgesic</other_name>
    <other_name>subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/= to 50 years.&#xD;
&#xD;
          2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the Structured&#xD;
             Clinical Interview for the DSM IV (SCID-IV).&#xD;
&#xD;
          3. Montgomery-Åsberg Depression Rating Scale (MADRS) &gt;/= to 15.&#xD;
&#xD;
          4. Has or agrees to establish a clinical relationship with primary care physician (PCP).&#xD;
&#xD;
          5. Availability of an informant (e.g., emergency contact).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent.&#xD;
&#xD;
          2. Depressive symptoms not severe enough i.e.,Montgomery-Åsberg Depression Rating Scale (&#xD;
             MADRS) &lt; 15 at the baseline assessments.&#xD;
&#xD;
          3. Dementia, as defined by The Modified Mini-Mental State (3MS) examination &lt; 84 and&#xD;
             clinical evidence of dementia (e.g., memory impairment, executive dysfunction,&#xD;
             agnosia, apraxia, aphasia, with functional impairment).&#xD;
&#xD;
          4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective&#xD;
             disorder, schizophreniform disorder, delusional disorder, or current psychotic&#xD;
             symptoms, as diagnosed by the Structured Clinical Interview for DSM (SCID).&#xD;
&#xD;
          5. Abuse of or dependence on alcohol or other substances within the past 3 months as&#xD;
             determined by SCID, and confirmed by study physician interview.&#xD;
&#xD;
          6. Alcohol use amounting to 15 or more drinks per week or drinking 5 or more drinks on&#xD;
             one occasion during any given week.&#xD;
&#xD;
          7. High risk for suicide (e.g., active suicidal ideation (SI) and/or current/recent&#xD;
             intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling&#xD;
             to be hospitalized). Urgent psychiatric referral will be made in these cases.&#xD;
&#xD;
          8. Contraindication to venlafaxine extended release (XR) or BPN as determined by study&#xD;
             physician including history of intolerance of either venlafaxine XR or BPN in the&#xD;
             study target dosage range (venlafaxine XR at up to 300 mg/day; BPN at up to 2 mg/day).&#xD;
&#xD;
          9. Inability to communicate in English (i.e., interview cannot be conducted without an&#xD;
             interpreter; subject largely unable to understand questions and cannot respond in&#xD;
             English).&#xD;
&#xD;
         10. Non-correctable clinically significant sensory impairment (i.e., cannot hear well&#xD;
             enough to cooperate with interview).&#xD;
&#xD;
         11. Unstable medical illness, including delirium, uncontrolled diabetes mellitus,&#xD;
             hypertension, or cerebrovascular or cardiovascular risk factors that are not under&#xD;
             medical management. This will be determined based on information from the patient's&#xD;
             personal physician and study physician's clinical judgment. Referral to the patient's&#xD;
             personal physician or to a general practitioner will be made in these cases. Sodium&#xD;
             and glucose levels done in the past 6 months are also reviewed before a subject begins&#xD;
             study medication to determine if an illness is stable or uncontrolled. Individual lab&#xD;
             parameters may deviate from normal without any associated pathophysiology or negative&#xD;
             clinical affect; therefore we will follow the guide below before beginning starting&#xD;
             any study medication.&#xD;
&#xD;
             Sodium value of 135 but asymptomatic= consider to be normal and proceed without&#xD;
             further testing.&#xD;
&#xD;
             Sodium value of 134= repeat sodium. If value continues to be at 134 or higher and&#xD;
             subject is asymptomatic, continue study participation but recheck sodium level after&#xD;
             one week of exposure to study medication to confirm it has stayed stable.&#xD;
&#xD;
             Sodium value of 133 or less= will evaluate subject's medication list to suggest&#xD;
             possibly removing other medications which may be contributing to low sodium (in&#xD;
             collaboration with their PCP), suggest fluid restriction and require repeat sodium&#xD;
             that is normal range prior to commencing study.&#xD;
&#xD;
             Glucose &lt; 275 and asymptomatic= stable to proceed but will communicate value to PCP&#xD;
             with participants permission.&#xD;
&#xD;
             (see exclusion #17 for information on hepatic function lab parameters)&#xD;
&#xD;
         12. Subjects taking psychotropic medications that cannot be safely tapered and&#xD;
             discontinued prior to study initiation. The following exceptions are allowed if they&#xD;
             have been taken at a stable dose for at least 4 weeks prior to study entry and there&#xD;
             is not a plan to change the dose during the next 28 weeks: benzodiazepines up to 2&#xD;
             mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon,&#xD;
             eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g.,&#xD;
             neuropathy).&#xD;
&#xD;
         13. History of opiate abuse or dependence.&#xD;
&#xD;
         14. Severe pain, defined as &gt;/= 7 on 0-10 numeric rating scale for pain.&#xD;
&#xD;
         15. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir,&#xD;
             ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir,&#xD;
             telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil,&#xD;
             diltiazem)&#xD;
&#xD;
         16. Refusal to stop all opioids (to avoid precipitating opioid withdrawal).&#xD;
&#xD;
         17. Hepatic impairment- aspartate aminotransferase (AST) /alanine aminotransferase (ALT) &gt;&#xD;
             1.5 times upper normal. If AST and ALT are within 1.5 times the upper limit, and&#xD;
             subjects are asymptomatic, they will be considered medically stable to participate&#xD;
&#xD;
         18. Estimated Glomerular Filtration Rate (GFR) &lt; 20 ml/min.&#xD;
&#xD;
         19. Inability/refusal to identify a person as an emergency contact.&#xD;
&#xD;
         20. Pregnancy&#xD;
&#xD;
         21. Contraindications to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan F. Karp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic, University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>April 26, 2018</results_first_submitted>
  <results_first_submitted_qc>May 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jordan F. Karp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Buprenorphine</keyword>
  <keyword>Receptors, opioid</keyword>
  <keyword>Receptors, opioid kappa and mu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Buprenorphine&#xD;
Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Buprenorphine&#xD;
Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: matched placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="9.7"/>
                    <measurement group_id="B2" value="65.6" spread="7.5"/>
                    <measurement group_id="B3" value="65.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Measure of depression severity, range of 0-60&#xD;
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.&#xD;
Greater mean change represents better outcome.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Measure of depression severity, range of 0-60&#xD;
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.&#xD;
Greater mean change represents better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in MADRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="8.94"/>
                    <measurement group_id="O2" value="4.09" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final MADRS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.93" spread="8.68"/>
                    <measurement group_id="O2" value="14.64" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Symptom Inventory--Anxiety Subscale (BSI)</title>
        <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.&#xD;
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Symptom Inventory--Anxiety Subscale (BSI)</title>
          <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.&#xD;
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in BSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.39"/>
                    <measurement group_id="O2" value="0.06" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final BSI Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.94"/>
                    <measurement group_id="O2" value="0.64" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a period of 1 year and six months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>death was determined to be due to cardiac disease unrelated to study participation.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>severe abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and hypertension</sub_title>
                <description>These two condition were listed as the reasons for hospitalization</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>hospitalization for pneumonia</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased plasma glucose level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased pulse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased Sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jordan F. Karp</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-6048</phone>
      <email>karpjf@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

